Logo

MorphoSys Could Earn Up to $24M in New Roche Pact

Mar 01, 2006

NEW YORK, March 1 (GenomeWeb News) - Roche and MorphoSys, a German synthetic antibodies producer, have expanded their six-year partnership to develop therapeutic antibodies in oncology, the companies said today.

 

The firms will collaborate on two new antibody programs in oncology, from which MorphoSys will receive an upfront payment and may receive additional research funding and future event payments totaling more than €10 million ($11.9 million) per program, plus potential royalties, according to the companies.

 

The companies also said that Roche will be responsible for preclinical and clinical development as well as subsequent marketing of all resulting products.

 

The new agreement is expanded from a collaboration on Alzheimer's disease that Roche and MorphoSys began in 2000.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.